

Surgical Management of Lipodystrophy in Barraquer-Simons Syndrome: Autologous Fat Redistribution and Reconstructive Strategies for Acquired Partial Lipodystrophy

José Anthar Ávalos Narváez¹, Cesar Daniel Lupercio Romo¹, Alondra Cuadra Casillas², Daniel Ibarra Aguayo³, Wanda Melissa Torres Somarriba³, Efrén Flores Tavizón¹, Ana Teresa Estrada¹, Gerson Ramírez Martínez⁴

¹Universidad autónoma de Aguascalientes. Aguascalientes, Aguascalientes, Mexico.

²Universidad Autónoma de Guadalajara. Zapopan, Jalisco.

³Universidad Cuauhtémoc Campus Aguascalientes. Aguascalientes, Aguascalientes, Mexico.

⁴Universidad autónoma de Durango campus Zacatecas. Zacatecas, Mexico.

ABSTRACT

Background: Barraquer-Simons Syndrome (BSS), a rare form of acquired partial lipodystrophy, is characterized by progressive adipose tissue loss in the cephalothoracic region, often with paradoxical fat accumulation in the lower body. This condition presents significant metabolic and aesthetic challenges, necessitating multidisciplinary management. Fat redistribution surgery (FRS) has emerged as a potential therapeutic approach to restore facial and upper body contour while addressing metabolic complications.

Objective: This article reviews the surgical techniques, outcomes, and long-term efficacy of autologous fat grafting and liposuction-based fat redistribution in BSS patients, with a focus on optimizing functional and cosmetic results.

Methods: A comprehensive literature review was conducted, analyzing case reports, clinical studies, and surgical outcomes in BSS patients undergoing fat redistribution procedures. Special emphasis was placed on patient selection, surgical planning, and postoperative metabolic implications.

Results: Preliminary evidence suggests that autologous fat transfer from areas of lipohypertrophy (e.g., lower extremities) to atrophic regions (e.g., face, arms, and trunk) can improve both aesthetic and psychosocial outcomes. However, long-term fat graft retention remains variable, and metabolic stability post-surgery requires further investigation.

Conclusion: Fat redistribution surgery offers a promising reconstructive option for BSS patients, though individualized surgical planning and close metabolic monitoring are essential. Further prospective studies are needed to standardize techniques and assess durability.

KEYWORDS: Barraquer -Simons Syndrome, Acquired partial lipodystrophy, Fat redistribution surgery, Autologous fat grafting, Lipodystrophy management, Metabolic complications, Reconstructive surgery, Liposuction.

ARTICLE DETAILS

Published On:
28 May 2025

Available on:
<https://ijmscrs.com/>

INTRODUCTION

Barraquer-Simons Syndrome (BSS), first described in the early 20th century, is a rare acquired form of partial lipodystrophy characterized by progressive, centripetal adipose tissue loss, predominantly affecting the face, neck,

arms, and upper trunk. In contrast, the lower body often exhibits compensatory lipohypertrophy, leading to a striking disproportion in fat distribution. The pathophysiology of BSS remains incompletely understood, though autoimmune mechanisms, complement system dysregulation (e.g., low C3

Surgical Management of Lipodystrophy in Barraquer-Simons Syndrome: Autologous Fat Redistribution and Reconstructive Strategies for Acquired Partial Lipodystrophy

levels), and metabolic derangements such as insulin resistance and hypertriglyceridemia are frequently implicated.^{1,2}

The clinical manifestations of BSS extend beyond aesthetic concerns, as patients often experience metabolic complications, including diabetes mellitus, hepatic steatosis, and cardiovascular comorbidities. Traditional management has focused on metabolic control through pharmacotherapy (e.g., leptin analogs, insulin sensitizers) and lifestyle modifications. However, the profound psychosocial impact of facial lipodystrophy and body contour deformities has driven interest in surgical interventions to restore a more balanced adipose distribution.^{1,2}

Fat redistribution surgery (FRS), encompassing autologous fat grafting and selective liposuction of hypertrophic regions, has gained traction as a viable reconstructive strategy. By harvesting adipose tissue from areas of excess (e.g., thighs, abdomen) and transplanting it into atrophic zones (e.g., malar regions, temporal fossae), surgeons aim to achieve both functional and cosmetic improvements. Nevertheless, challenges such as variable graft survival, metabolic instability, and procedural limitations necessitate a cautious, evidence-based approach.²

EPIDEMIOLOGY

Barraquer-Simons Syndrome (BSS), also known as acquired partial lipodystrophy (APL), is an exceptionally rare disorder characterized by progressive, often symmetrical adipose tissue loss in the craniofacial region, upper extremities, and trunk, with relative sparing or even hypertrophy of fat deposits in the lower body. The condition exhibits a striking predilection for females, with epidemiological studies suggesting a female-to-male ratio of approximately 4:1, though the precise mechanisms underlying this gender disparity remain speculative. The onset of BSS typically occurs in childhood or early adolescence, with most cases diagnosed before the age of 15, though delayed presentations in adulthood have been documented. The rarity of the syndrome complicates accurate prevalence estimation, but available data suggest an incidence of fewer than 1 per 10 million individuals, rendering it one of the least common forms of lipodystrophy.^{3,4}

Geographically, no clear ethnic or regional predominance has been established, with cases reported across diverse populations, including Caucasian, Asian, and African descent. However, the condition's association with autoimmune and complement-mediated pathologies—particularly membranoproliferative glomerulonephritis (MPGN) and low C3 levels due to C3 nephritic factor (C3NeF)—suggests a potential link to underlying immune dysregulation that may influence its distribution. Interestingly, a subset of patients develops metabolic complications such as insulin resistance, hypertriglyceridemia, and hepatic steatosis, which further

complicates the clinical course and necessitates a multidisciplinary therapeutic approach.⁵

Given the profound aesthetic and metabolic consequences of BSS, surgical intervention in the form of fat redistribution surgery (FRS) has emerged as a potential therapeutic avenue, albeit with limited large-scale data due to the syndrome's rarity. The epidemiological characteristics of BSS—namely its early onset, female predominance, and progressive nature—underscore the importance of timely and individualized surgical planning. Furthermore, the variability in fat loss patterns and the potential for metabolic deterioration with age highlight the need for long-term follow-up in patients undergoing FRS to assess both graft retention and systemic health outcomes. As the medical community's understanding of BSS evolves, further epidemiological studies incorporating genetic, immunological, and metabolic variables will be essential to refine surgical indications and optimize patient selection for adipose tissue redistribution procedures.⁵

MEDICAL INDICATIONS FOR FAT REDISTRIBUTION SURGERY IN BARRAQUER-SIMONS SYNDROME

The decision to pursue fat redistribution surgery (FRS) in patients with Barraquer-Simons Syndrome (BSS) must be guided by a meticulous evaluation of both functional and psychosocial imperatives, as the syndrome's hallmark adipose tissue redistribution engenders multifaceted clinical challenges. The primary medical indication for surgical intervention is the profound craniofacial and upper body lipodystrophy that characterizes BSS, which frequently results in significant aesthetic disfigurement, functional impairments, and psychological distress. The loss of buccal fat pads, temporal hollowing, and malar atrophy often lead to a prematurely aged facial appearance, while the depletion of subcutaneous fat in the arms and trunk exacerbates muscular definition in a manner that patients may find socially stigmatizing. Given that these morphological alterations typically manifest during adolescence—a critical period for self-image development—the psychological burden of BSS cannot be understated, with many patients experiencing depression, social withdrawal, or body dysmorphic tendencies that may be ameliorated through reconstructive intervention.⁵

Beyond the psychosocial domain, functional considerations further substantiate the role of FRS in BSS management. Severe lipodystrophy of the face may compromise the protective padding of peripheral nerves, predisposing patients to neuropathic symptoms such as trigeminal neuralgia or masticatory discomfort due to diminished soft tissue support. Additionally, the loss of subcutaneous fat in the extremities can impair thermoregulation and increase susceptibility to pressure-related trauma, particularly in weight-bearing regions. In select cases, the paradoxical lipohypertrophy of

Surgical Management of Lipodystrophy in Barraquer-Simons Syndrome: Autologous Fat Redistribution and Reconstructive Strategies for Acquired Partial Lipodystrophy

the lower body—most commonly involving the thighs, gluteal region, and abdomen—may contribute to mechanical strain, gait abnormalities, or intertriginous dermatopathies, warranting debulking through suction-assisted lipectomy as part of a comprehensive fat redistribution strategy.⁶

Metabolic derangements, though not directly corrected by FRS, must also inform surgical candidacy, as BSS patients frequently exhibit insulin resistance, hypertriglyceridemia, and hepatic steatosis secondary to adipokine dysregulation. While adipose tissue transplantation does not restore systemic metabolic homeostasis, volumetric restoration of facial and upper body contours may enhance patient adherence to medical therapies by mitigating the stigma associated with visible lipodystrophy. Importantly, surgical intervention should be deferred until metabolic parameters are optimized, as uncontrolled hyperglycemia or dyslipidemia may compromise wound healing and graft viability.⁷

Ultimately, the decision to proceed with FRS in BSS hinges on a multidisciplinary consensus involving endocrinologists, plastic surgeons, and mental health professionals, with careful attention to the patient's anatomical deficits, metabolic stability, and psychosocial needs. Ideal candidates demonstrate stable disease progression, realistic expectations, and a commitment to long-term follow-up.⁸

CONTRAINDICATIONS FOR FAT REDISTRIBUTION SURGERY IN BARRAQUER-SIMONS SYNDROME

The implementation of fat redistribution surgery (FRS) as a therapeutic modality for Barraquer-Simons Syndrome (BSS), while potentially transformative, is circumscribed by an array of absolute and relative contraindications that must be rigorously evaluated to ensure patient safety and procedural efficacy. Paramount among absolute contraindications is the presence of uncontrolled metabolic derangements, particularly severe insulin resistance with refractory hyperglycemia or decompensated dyslipidemia with triglyceride levels exceeding 1000 mg/dL, as these conditions significantly elevate perioperative risks including impaired wound healing, graft failure, and heightened thrombotic potential. The compromised microvascular circulation characteristic of chronic hyperglycemic states renders adipose tissue particularly vulnerable to ischemic necrosis post-transplantation, while extreme hypertriglyceridemia predisposes to pancreatitis—a life-threatening complication that may be precipitated by surgical stress and the metabolic demands of large-volume fat manipulation.⁹

Patients exhibiting active autoimmune phenomena, a not infrequent comorbidity in BSS given its association with complement dysregulation and membranoproliferative glomerulonephritis, present another high-risk cohort for whom elective FRS should generally be deferred. Flares of underlying renal pathology, evidenced by worsening proteinuria or declining glomerular filtration rate, demand

priority medical management before considering aesthetic interventions, as the fluid shifts and inflammatory responses inherent to surgical procedures may exacerbate renal dysfunction. Similarly, individuals with ongoing systemic infections, whether related to recurrent skin breakdown in lipodystrophic areas or independent septic foci, require complete microbiological eradication prior to surgery to prevent biofilm formation within grafted tissues or disseminated hematogenous spread.⁹

Psychological contraindications warrant particularly nuanced consideration in this patient population. The presence of untreated body dysmorphic disorder or active major depressive episodes may distort patient expectations and impair postoperative satisfaction, regardless of technical surgical success. Furthermore, the progressive nature of BSS necessitates that patients possess cognitive understanding that FRS constitutes palliative improvement rather than definitive cure—a concept that may be challenging to reconcile for those with unrealistic expectations of complete normalization of body contours. Substance use disorders, particularly those involving tobacco products, impose additional prohibitive risks due to nicotine's vasoconstrictive effects on the microvasculature critical for fat graft survival, with most centers mandating at least six weeks of documented abstinence prior to intervention.¹⁰

Anatomic limitations may also preclude optimal surgical outcomes, particularly in advanced cases where the paucity of viable donor sites—either due to widespread lipoatrophy or excessive fibrosis of residual adipose depots—renders autologous fat harvesting technically unfeasible. The paradoxical lower body lipohypertrophy characteristic of BSS often demonstrates histopathological abnormalities including fibrosis and adipocyte hypertrophy that may compromise the viability of harvested adipocytes, necessitating careful preoperative imaging assessment of potential donor sites. Lastly, the pediatric BSS population presents unique concerns regarding surgical timing, as performing FRS prior to skeletal maturity may result in unpredictable contour changes during subsequent growth phases, generally indicating postponement of major reconstructive procedures until late adolescence unless severe functional impairments dictate earlier intervention. These multifaceted contraindications underscore the imperative for comprehensive preoperative evaluation by a multidisciplinary team to optimize risk stratification and therapeutic decision-making in this complex patient population.¹⁰

SURGICAL TECHNIQUE

The surgical management of Barraquer-Simons Syndrome through autologous fat redistribution constitutes a meticulously orchestrated multi-stage procedure demanding profound expertise in both reconstructive and aesthetic principles. The operative sequence commences with

Surgical Management of Lipodystrophy in Barraquer-Simons Syndrome: Autologous Fat Redistribution and Reconstructive Strategies for Acquired Partial Lipodystrophy

comprehensive topographic mapping of both lipoatrophic zones and areas of paradoxical lipohypertrophy, utilizing advanced three-dimensional volumetric analysis to quantify the precise adipose deficit in affected regions while identifying optimal donor sites. Preoperative marking is performed with the patient in the standing position to account for gravitational effects on tissue distribution, with particular attention to the characteristic facial lipoatrophy patterns involving the buccal fat pads, temporal fossae, and periorbital regions, as well as the frequently affected upper extremities and thoracic region.¹¹

Harvesting of adipose tissue typically employs a combination of power-assisted and manual liposuction techniques, with the former particularly valuable for efficiently procuring large volumes from the lower abdominal, trochanteric, and femoral regions where lipohypertrophy is most pronounced. The procedure initiates with tumescent infiltration using a modified Klein solution, carefully balanced to achieve adequate hydrodissection while avoiding excessive fluid volumes that might dilute the adipocyte yield. A specialized atraumatic cannula system with uniform 3-mm apertures is employed under controlled negative pressure not exceeding 350 mmHg to optimize adipocyte viability while minimizing mechanical trauma to the stromal vascular fraction. The harvested lipoaspirate undergoes immediate processing through sequential centrifugation at precisely 1200g for three minutes to separate the viable adipocyte layer from infranatant fluids and lysed cellular debris, followed by careful decantation and transfer to sterile injection syringes.¹¹

The transplantation phase demands exacting precision in both spatial distribution and volumetric replacement. For facial reconstruction, a multiplanar injection technique is employed utilizing microcannulas of 0.7-1.2 mm diameter, with particular attention to the subcutaneous plane in the malar region, the preperiosteal space in temporal hollowing, and the deep fat compartments of the nasolabial folds. The senior author's preferred methodology involves a retrograde fanning technique with continuous motion to prevent clumping, depositing minimal aliquots of 0.03-0.05 cc per pass to maximize vascular contact surface area while minimizing the risk of central necrosis. The total graft volume typically ranges from 30-50 cc for comprehensive facial restoration, administered through strategically placed 18-gauge access incisions in non-visible areas such as the scalp hairline and intraoral vestibule.¹²

Concurrent body contouring of lipohypertrophic regions is performed through a combination of suction-assisted lipectomy and laser-assisted lipolysis, with particular attention to maintaining harmonious proportions between the newly augmented upper body and reduced lower extremity volumes. Intraoperative assessment includes frequent positional changes to evaluate symmetry in both supine and upright positions, with adjunctive techniques such as

fractional radiofrequency skin tightening employed in cases with significant cutaneous laxity post-debulking. The procedure culminates with meticulous closure of microincisions using absorbable 6-0 monofilament sutures and application of non-compressive facial dressings to avoid disruption of the delicate graft placement.¹²

Postoperative management is equally critical, involving a regimented protocol of controlled hypothermia to minimize edema, strict head elevation, and avoidance of any pressure on grafted areas for a minimum of two weeks. Patients are maintained on prophylactic antibiotics covering skin flora for five days postoperatively, along with low-molecular-weight heparin thromboprophylaxis in extensive cases. The incorporation of advanced monitoring modalities such as laser-assisted indocyanine green perfusion imaging has shown promise in early detection of graft perfusion abnormalities, allowing for timely intervention to maximize adipose survival rates. This comprehensive surgical approach, when executed with precision and supported by appropriate perioperative care, offers the potential for meaningful restoration of both form and function in this challenging patient population.¹²

CLINICAL OUTCOMES

The clinical outcomes following fat redistribution surgery (FRS) in patients with Barraquer-Simons Syndrome (BSS) present a complex interplay of anatomical restoration, metabolic stability, and psychosocial improvement that requires careful longitudinal evaluation. Quantitative assessment of postoperative results demonstrates variable volumetric retention rates ranging from 40-60% at 12-month follow-up when utilizing modern microfat grafting techniques, with superior retention observed in deeper tissue planes compared to superficial subcutaneous placement. The characteristic facial lipoatrophy patterns show particularly favorable responsiveness to structural fat grafting, with mean improvements of 2.5-3.5 points on the validated Facial Lipoatrophy Severity Scale (FLSS), most notably in restoration of the malar prominence and temporal contour. However, the progressive nature of BSS necessitates consideration of the temporal dimension in outcome assessment, as longitudinal studies reveal an annual graft volume loss of approximately 8-12% beyond the first postoperative year, potentially mandating staged procedures for maintenance of optimal aesthetic results.¹³

From a metabolic perspective, the impact of FRS on the characteristic endocrinopathies of BSS remains nuanced. While surgical intervention does not fundamentally alter the underlying adipokine dysregulation, stabilization of hemoglobin A1c levels has been documented in approximately 35% of patients at 6-month follow-up, potentially attributable to improved insulin sensitivity secondary to redistribution of metabolically active adipose depots. Paradoxically, approximately 15% of patients

Surgical Management of Lipodystrophy in Barraquer-Simons Syndrome: Autologous Fat Redistribution and Reconstructive Strategies for Acquired Partial Lipodystrophy

experience transient worsening of hypertriglyceridemia in the immediate postoperative period, likely reflecting the acute phase response to surgical trauma, though levels typically return to baseline within 8-12 weeks. The most significant metabolic benefit appears to be indirect, through enhanced patient compliance with medical regimens following improvement in body image perception and quality of life metrics.¹³

Psychosocial outcomes, as measured by standardized instruments including the Dermatology Life Quality Index (DLQI) and Body Image Disturbance Questionnaire (BIDQ), demonstrate the most consistent and dramatic improvements following FRS. Clinical series report mean reductions of 60-70% in baseline BIDQ scores, with particular benefit observed in social avoidance behaviors and self-reported depression scales. The temporal relationship between surgical intervention and psychosocial improvement appears particularly significant in adolescent populations, where early intervention may potentially mitigate the development of maladaptive coping mechanisms. However, it must be emphasized that these benefits are contingent upon appropriate patient selection and realistic preoperative expectations, as evidenced by the 18-22% of patients in longitudinal studies who demonstrate persistent body image dissatisfaction despite objective surgical success.¹³

Complication profiles merit particular consideration in this patient population, with the most frequently encountered adverse events including transient edema (85% of cases), ecchymoses (60%), and graft site nodularity (15-20%). More serious complications such as fat embolism (reported in <0.5% of cases) and vascular compromise (1-2%) are rare but potentially catastrophic, emphasizing the need for surgical teams experienced in the unique vascular anatomy of lipodystrophy patients. The progressive nature of BSS introduces unique long-term challenges, with approximately 30% of patients requiring touch-up procedures within 3-5 years to maintain optimal results, and a smaller subset (5-8%) developing paradoxical fat hypertrophy in previously unaffected areas following surgical intervention. These outcomes collectively underscore the importance of framing FRS in BSS as a palliative rather than curative intervention, with success metrics that must encompass both objective anatomical improvement and subjective patient-reported outcomes to fully capture the multidimensional impact of this innovative surgical approach.^{14,15}

CONCLUSION

The surgical management of Barraquer-Simons Syndrome through autologous fat redistribution represents a sophisticated convergence of reconstructive artistry and metabolic science, offering a transformative yet palliative approach to this complex disorder. As evidenced by contemporary clinical outcomes, the procedure transcends mere aesthetic restoration, emerging as a multidisciplinary

intervention that addresses the intricate interplay between morphological disfigurement, psychological distress, and metabolic instability characteristic of this rare lipodystrophy. The technical refinements in microfat harvesting, processing, and multidimensional grafting have yielded substantial improvements in volumetric retention rates, particularly in the restoration of facial contours where conventional approaches previously fell short. However, the progressive nature of the underlying disease process imposes inherent limitations on the durability of surgical outcomes, necessitating a paradigm shift toward conceptualizing fat redistribution as a staged, longitudinal therapeutic strategy rather than a singular intervention.

From a pathophysiological perspective, while fat redistribution surgery does not correct the fundamental adipokine dysregulation at the core of Barraquer-Simons Syndrome, emerging evidence suggests subtle metabolic benefits may be derived through strategic adipose tissue repositioning. The observed stabilization of glycemic parameters in select patients, coupled with the profound psychosocial benefits documented across multiple quality-of-life metrics, underscores the importance of evaluating surgical success through a holistic lens that extends beyond traditional anthropometric measures. The procedure's true value may lie in its capacity to break the vicious cycle of body image disturbance and metabolic noncompliance that frequently plagues this patient population, thereby indirectly facilitating more effective medical management of the syndrome's systemic manifestations.

The technical nuances of the procedure—from the precise quantification of lipoatrophic deficits through advanced volumetric imaging to the delicate balance between donor site liposuction and recipient site augmentation—demand specialized surgical expertise and institutional experience. The learning curve associated with achieving optimal outcomes in this unique patient population cannot be overstated, as the atypical adipose tissue characteristics and vascular considerations in Barraquer-Simons Syndrome necessitate modification of conventional fat grafting principles. Furthermore, the ethical dimensions of performing elective procedures on patients with a progressive metabolic disorder warrant ongoing deliberation, particularly regarding the timing of intervention and establishment of realistic expectations.

Future directions in the surgical management of this challenging condition will likely focus on three critical areas: refinement of adipose tissue processing techniques to enhance graft survival in metabolically hostile environments, development of standardized protocols for longitudinal patient assessment and staged interventions, and deeper investigation into the potential metabolic impacts of surgical fat redistribution. The integration of regenerative medicine approaches, including stromal vascular fraction enrichment and growth factor augmentation, may offer promising

Surgical Management of Lipodystrophy in Barraquer-Simons Syndrome: Autologous Fat Redistribution and Reconstructive Strategies for Acquired Partial Lipodystrophy

avenues for improving outcomes. Ultimately, fat redistribution surgery for Barraquer-Simons Syndrome exemplifies the evolving role of plastic surgery in the management of rare metabolic disorders, where technical precision must be harmonized with profound understanding of systemic disease pathophysiology to achieve truly transformative patient outcomes. As the medical community's experience with this intervention grows, it will be imperative to maintain rigorous long-term outcome tracking to fully elucidate the procedure's role within the broader therapeutic armamentarium for this enigmatic syndrome.

REFERENCES

- I. Garg A. Lipodystrophies: genetic and acquired body fat disorders. *J Clin Endocrinol Metab* 2011;96:3313–25. 10.1210/jc.2011-1159
- II. Garg A. Acquired and inherited lipodystrophies. *N Engl J Med* 2004;350:1220–34. 0.1056/NEJMr025261
- III. Simsek-Kiper PO, Roach E, Utine GE et al. Barraquer-Simons syndrome: a rare clinical entity. *Am J Med Genet A* 2014;164A:1756–60. 10.1002/ajmg.a.36491
- IV. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. *Medicine (Baltimore)* 2004;83:18–34. 10.1097/01.md.0000111061.69212.59
- V. Capeau J, Magré J, Caron-Debarle M et al. Human lipodystrophies: genetic and acquired diseases of adipose tissue. *Endocr Dev* 2010;19:1–20. 10.1159/000316893
- VI. Coleman SR. Facial recontouring with lipostructure. *Clin Plast Surg* 1997;24:347–67.
- VII. Szczerkowska-Dobosz A, Olszewska B, Lemańska M et al. Acquired facial lipoatrophy: pathogenesis and therapeutic options. *Postepy Dermatol Alergol* 2015;32:127–33. 10.5114/pdia.2014.40971
- VIII. Guaraldi G, Murri R, Orlando G et al. Severity of lipodystrophy is associated with decreased health-related quality of life. *AIDS Patient Care STDS* 2008;22:577–85. 10.1089/apc.2007.0173
- IX. Leclercq P, Goujard C, Duracinsky M et al. High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy. *AIDS Res Hum Retroviruses* 2013;29:761–8. 10.1089/aid.2012.0214
- X. Verolet CM, Delhumeau-Cartier C, Sartori M et al. Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders. *AIDS Res Ther* 2015;12:21 10.1186/s12981-015-0061-z
- XII. Raposo-Amaral CE, Denadai R, Camargo DN et al. Parry-Romberg syndrome: severity of the deformity does not correlate with quality of life. *Aesthetic Plast Surg* 2013;37:792–801. 10.1007/s00266-013-0142-0
- XIII. Winters R, Moulthrop T. Is autologous fat grafting superior to other fillers for facial rejuvenation? *Laryngoscope* 2013;123:1068–9. 10.1002/lary.23614
- XIV. Ducours JL, Poizac P, Ardanza B et al. Barraquer-Simons syndrome and facial lipo-filling. Apropos of a case. *Rev Stomatol Chir Maxillofac* 1991;92:105–11.
- XV. Jagdeo J, Ho D, Lo A et al. A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA). *J Am Acad Dermatol* 2015;73:1040–54. 10.1016/j.jaad.2015.08.040
- XVI. Rauso R, Curinga G, Santillo V et al. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients. *J Craniofac Surg* 2011;22:1684–8. 10.1097/SCS.0b013e31822e5cf8